PUBLISHER: The Business Research Company | PRODUCT CODE: 2035953
PUBLISHER: The Business Research Company | PRODUCT CODE: 2035953
Hepatitis C virus (HCV) viral load testing is a laboratory procedure that quantifies the amount of hepatitis C virus (HCV RNA) in a patient's bloodstream. It is used to confirm active infection and to monitor the effectiveness of antiviral therapy during and after treatment.
The key technologies of hepatitis C virus (HCV) viral load testing include polymerase chain reaction, nucleic acid sequence-based amplification, transcription-mediated amplification, and others. Polymerase chain reaction (PCR) is a laboratory technique used to amplify specific DNA sequences, creating millions of copies from a small DNA sample. Product types include instruments, kits and reagents, and software and services, supporting sample types such as blood, plasma, serum, and others. End users include hospitals and clinics, diagnostic laboratories, blood banks, and others.
Tariffs on imported diagnostic instruments, PCR reagents, and molecular testing components are impacting the hepatitis C virus viral load testing market by increasing costs for laboratories and healthcare providers. Segments such as instruments and kits and reagents are most affected, particularly in regions dependent on imported molecular diagnostic systems, including parts of Asia-Pacific, Latin America, and Africa. Higher procurement costs may slow adoption in resource-limited settings; however, tariffs are also encouraging domestic manufacturing of reagents and localized production of testing kits, fostering regional self-reliance and supply chain resilience in the long term.
The hcv viral load testing market research report is one of a series of new reports from The Business Research Company that provides hcv viral load testing market statistics, including hcv viral load testing industry global market size, regional shares, competitors with a hcv viral load testing market share, detailed hcv viral load testing market segments, market trends and opportunities, and any further data you may need to thrive in the hcv viral load testing industry. This hcv viral load testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hepatitis c virus (hcv) viral load testing market size has grown strongly in recent years. It will grow from $1.39 billion in 2025 to $1.48 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising global prevalence of hepatitis c infections, increasing awareness of early diagnosis, expansion of diagnostic laboratory infrastructure, adoption of nucleic acid amplification technologies, growing availability of antiviral therapies.
The hepatitis c virus (hcv) viral load testing market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing government screening programs, growing demand for precision viral load monitoring, expansion of decentralized testing facilities, rising investment in molecular diagnostics, technological advancements in high-sensitivity hcv rna assays. Major trends in the forecast period include increasing adoption of real-time PCR-based viral load testing, rising demand for early detection and monitoring of treatment response, growing use of automated high-throughput diagnostic platforms, expansion of point-of-care HCV RNA testing solutions, increasing standardization of viral load quantification assays.
The expansion of personalized medicine is expected to drive the growth of the hepatitis C virus (HCV) viral load testing market in the future. Personalized medicine is an approach to healthcare that tailors medical treatment and interventions according to an individual's genetic profile, lifestyle, and environmental factors to optimize clinical outcomes. The increasing adoption of personalized medicine is supported by advancements in genomic technologies, which facilitate precise disease profiling and targeted therapies that enhance treatment results while minimizing side effects. Hepatitis C viral load testing aids personalized medicine by measuring the virus quantity in a patient's blood, allowing clinicians to customize antiviral therapy selection, dosage, and treatment duration based on individual response and disease severity. For example, in February 2024, as per the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six in 2022, including seven cancer drugs and three therapies for other diseases and conditions. Hence, the expansion of personalized medicine is driving the growth of the hepatitis C virus (HCV) viral load testing market.
Leading companies operating in the hepatitis C virus (HCV) viral load testing market are focusing on obtaining regulatory approvals to expand access to rapid and highly accurate molecular diagnostic solutions. Regulatory approvals enable commercial distribution and clinical adoption of advanced nucleic acid amplification tests (NAATs), improving early diagnosis, treatment initiation, and disease monitoring. For example, in August 2025, Cepheid Inc., a US-based molecular diagnostics company, obtained a medical device license from Health Canada for its Xpert HCV Viral Load test. This assay is designed to detect and quantify hepatitis C virus (HCV) RNA and is conducted on Cepheid's GeneXpert System platform. The test delivers automated, real-time PCR-based results, enabling faster clinical decision-making, enhanced patient management, and broader access to decentralized HCV testing services.
In May 2024, Bruker Corporation, a US-based manufacturer of scientific instruments and analytical solutions, completed the acquisition of ELITechGroup for an undisclosed amount. With this acquisition, Bruker seeks to enhance its molecular diagnostics portfolio by incorporating ELITechGroup's innovative PCR-based infectious disease testing solutions and in vitro diagnostic assays, thereby growing its presence in the clinical diagnostics and infectious disease testing sector. ELITechGroup is a France-based molecular diagnostics company specializing in HCV viral load testing.
Major companies operating in the hepatitis c virus (hcv) viral load testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Danaher Corporation, Hologic Inc., Revvity, Bio-Rad Laboratories Inc., Qiagen N.V., Cepheid Inc., BioPerfectus Technologies Co. Ltd., Enzo Biochem Inc., Vela Diagnostics International Pte. Ltd., Altona Diagnostics GmbH, Certest Biotec S.L., Molbio Diagnostics Private Limited, 3B BlackBio Dx Limited, Anatolia Geneworks, GeneProof a.s., Sacace Biotechnologies S.r.l.
North America was the largest region in the hcv viral load testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hcv viral load testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the hcv viral load testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hepatitis C virus (HCV) viral load testing market consists of revenues earned by entities by providing services such as baseline viral load assessment, treatment monitoring, and sustained virologic response (SVR) testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis C virus (HCV) viral load testing market also includes sales of genexpert systems, automated RNA extraction systems, thermal cyclers, and fluorescence detection units. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hepatitis C Virus (HCV) Viral Load Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses hepatitis c virus (hcv) viral load testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for hepatitis c virus (hcv) viral load testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatitis c virus (hcv) viral load testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.